Svmuu News Ripple announced its participation in the Monetary Authority of Singapore's (MAS) BLOOM program, testing the application of its RLUSD stablecoin in cross-border trade payments within the regulatory sandbox. Ripple is collaborating with supply chain finance technology provider Unloq to pilot a system based on the XRP Ledger. This system uses RLUSD to automatically trigger cross-border trade payments when preset conditions (such as shipment verification) are met, aiming to replace the traditional trade finance processes that rely on manual verification and correspondent banking relationships.
The pilot utilizes Unloq's SC+ platform to integrate trade obligations, settlement conditions, and financing workflows into a single execution layer, with RLUSD on the XRP Ledger facilitating the fund flows. This marks Ripple's third significant move within three weeks, following the company's expansion of Ripple Payments into a full-stack stablecoin infrastructure platform and its acquisition of an Australian financial services license.
Ripple Tests RLUSD Stablecoin-Driven Trade Finance in Singapore's MAS Sandbox
Source:Odaily · Source Link
Disclaimer: This content reflects only the author’s personal views and does not constitute any investment or financial advice. If you discover any content that violates regulations,Click to Report
24H Trending
-
1
Billionaire investor Chase Coleman’s Tiger Global fund disclosed in its latest 13F filing that its top five growth stocks are all focused on AI infrastructure, including TSMC, NVIDIA, Amazon, Meta, and Google.
-
2
Will the BEAM token go to zero? Could it rise to $1,000? An in-depth analysis of the Beam network and its market prospects
-
3
Analysis of CRYSTAL’s Value and Investment Potential: An Examination of Multiple Projects and Risk Assessment
-
4
What Is CVP? An In-Depth Analysis of the PowerPool Ecosystem and the Investment Value of Its Token, CVP
-
5
Analysis: The State Street Healthcare ETF (XLV) has an expense ratio of 0.08% and a diversified portfolio, while the Invesco Biotechnology ETF (PBE) has an expense ratio of 0.58% and focuses on small-cap stocks; PBE is up 10.2% year-to-date, outperforming XLV.
-
6
QUARTZ Coin Analysis: An Overview of the Sandclock (QUARTZ) and Unique Network’s Quartz (QTZ) Projects
-
7
Ethereum Recent Rebound: Price Breaks Above $1,970, but Multiple Risks Remain
-
8
MARA Stock Valuation Analysis: Marathon Digital Holdings’ Transition to AI and Long-Term Investment Outlook
-
9
What Is JGN? Analysis of the JGN (Sword Saint Coin) Project’s Positioning, Features, and Value
-
10
NVIDIA and AMD: The Two Giants of AI Computing Power in 2026—An Analysis of Market Dynamics, Financial Performance, and Opportunities for Transition into Cryptocurrency Mining
Markets Today
Recommended Reading










